United Therapeutics Net Worth
United Therapeutics Net Worth Breakdown | UTHR |
United Therapeutics Net Worth Analysis
United Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including United Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of United Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform United Therapeutics' net worth analysis. One common approach is to calculate United Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares United Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing United Therapeutics' net worth. This approach calculates the present value of United Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of United Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate United Therapeutics' net worth. This involves comparing United Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into United Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if United Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding United Therapeutics' net worth research are outlined below:
| United Therapeutics is unlikely to experience financial distress in the next 2 years | |
| United Therapeutics has a strong financial position based on the latest SEC filings | |
| Over 100.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Disposition of 245 shares by Michael Benkowitz of United Therapeutics at 368.0761 subject to Rule 16b-3 |
United Therapeutics Quarterly Good Will |
|
United Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in United Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to United Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
United Therapeutics Target Price Consensus
United target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. United Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 16 | Buy |
Most United analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand United stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of United Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationUnited Therapeutics Target Price Projection
United Therapeutics' current and average target prices are 370.33 and 398.02, respectively. The current price of United Therapeutics is the price at which United Therapeutics is currently trading. On the other hand, United Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
United Therapeutics Market Quote on 23rd of January 2025
Target Price
Analyst Consensus On United Therapeutics Target Price
Know United Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as United Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading United Therapeutics backward and forwards among themselves. United Therapeutics' institutional investor refers to the entity that pools money to purchase United Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2024-09-30 | 621 K | Fuller & Thaler Asset Management Inc | 2024-09-30 | 568.4 K | Pacer Advisors, Inc. | 2024-09-30 | 566.7 K | Alliancebernstein L.p. | 2024-09-30 | 551.7 K | Hhg Plc | 2024-09-30 | 460.4 K | Genworth Financial Wealth Mgmt Inc | 2024-09-30 | 420 K | Swedbank Ab | 2024-09-30 | 414.9 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 401.5 K | Bank Of New York Mellon Corp | 2024-09-30 | 401.1 K | Blackrock Inc | 2024-09-30 | 5.3 M | Vanguard Group Inc | 2024-09-30 | 4.4 M |
Follow United Therapeutics' market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 16.58 B.Market Cap |
|
Project United Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.14 | 0.13 | |
| Return On Capital Employed | 0.17 | 0.18 | |
| Return On Assets | 0.12 | 0.13 | |
| Return On Equity | 0.15 | 0.16 |
When accessing United Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures United Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of United Therapeutics' profitability and make more informed investment decisions.
Evaluate United Therapeutics' management efficiency
United Therapeutics has return on total asset (ROA) of 0.1189 % which means that it generated a profit of $0.1189 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1881 %, meaning that it created $0.1881 on every $100 dollars invested by stockholders. United Therapeutics' management efficiency ratios could be used to measure how well United Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, United Therapeutics' Return On Capital Employed is relatively stable compared to the past year. As of 01/23/2025, Return On Assets is likely to grow to 0.13, while Return On Tangible Assets are likely to drop 0.13. At this time, United Therapeutics' Intangibles To Total Assets are relatively stable compared to the past year. As of 01/23/2025, Debt To Assets is likely to grow to 0.10, while Other Assets are likely to drop slightly above 284.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 115.09 | 120.85 | |
| Tangible Book Value Per Share | 112.90 | 118.54 | |
| Enterprise Value Over EBITDA | 8.11 | 10.85 | |
| Price Book Value Ratio | 1.98 | 1.88 | |
| Enterprise Value Multiple | 8.11 | 10.85 | |
| Price Fair Value | 1.98 | 1.88 | |
| Enterprise Value | 11.2 B | 11.8 B |
Examining the leadership quality of United Therapeutics offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Enterprise Value Revenue 4.8985 | Revenue | Quarterly Revenue Growth 0.229 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific United Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on United Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases United Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
United Therapeutics Corporate Filings
F4 | 22nd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
United Therapeutics Earnings Estimation Breakdown
The calculation of United Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of United Therapeutics is estimated to be 6.168325 with the future projection ranging from a low of 5.86 to a high of 6.49. Please be aware that this consensus of annual earnings estimates for United Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
5.86 Lowest | Expected EPS | 6.49 Highest |
United Therapeutics Earnings Projection Consensus
Suppose the current estimates of United Therapeutics' value are higher than the current market price of the United Therapeutics stock. In this case, investors may conclude that United Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and United Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 16 | 78.93% | 6.39 | 6.168325 | 22.78 |
United Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of United Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering United Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of United Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.United Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as United Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of United Therapeutics should always be considered in relation to other companies to make a more educated investment decision.United Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact United Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-10-30 | 2024-09-30 | 6.43 | 6.39 | -0.04 | 0 | ||
2024-07-31 | 2024-06-30 | 6.4 | 5.85 | -0.55 | 8 | ||
2024-05-01 | 2024-03-31 | 5.65 | 6.17 | 0.52 | 9 | ||
2024-02-21 | 2023-12-31 | 4.19 | 4.36 | 0.17 | 4 | ||
2023-11-01 | 2023-09-30 | 5.04 | 5.38 | 0.34 | 6 | ||
2023-08-02 | 2023-06-30 | 4.51 | 5.24 | 0.73 | 16 | ||
2023-05-03 | 2023-03-31 | 4.52 | 4.86 | 0.34 | 7 | ||
2023-02-22 | 2022-12-31 | 4.51 | 2.67 | -1.84 | 40 | ||
2022-11-02 | 2022-09-30 | 3.89 | 4.91 | 1.02 | 26 | ||
2022-08-03 | 2022-06-30 | 4.13 | 2.41 | -1.72 | 41 | ||
2022-05-04 | 2022-03-31 | 3.35 | 5.03 | 1.68 | 50 | ||
2022-02-24 | 2021-12-31 | 3.72 | 2.35 | -1.37 | 36 | ||
2021-11-03 | 2021-09-30 | 3.59 | 3.42 | -0.17 | 4 | ||
2021-08-04 | 2021-06-30 | 3.02 | 3.65 | 0.63 | 20 | ||
2021-05-05 | 2021-03-31 | 2.94 | 0.61 | -2.33 | 79 | ||
2021-02-24 | 2020-12-31 | 3.14 | 2.19 | -0.95 | 30 | ||
2020-10-28 | 2020-09-30 | 2.83 | 3.86 | 1.03 | 36 | ||
2020-07-29 | 2020-06-30 | 2.87 | 2.41 | -0.46 | 16 | ||
2020-04-29 | 2020-03-31 | 2.75 | 3.12 | 0.37 | 13 | ||
2020-02-26 | 2019-12-31 | 2.68 | 1.2 | -1.48 | 55 | ||
2019-10-30 | 2019-09-30 | 2.44 | 3.16 | 0.72 | 29 | ||
2019-07-31 | 2019-06-30 | 2.49 | 4.11 | 1.62 | 65 | ||
2019-05-01 | 2019-03-31 | 2.78 | 2.81 | 0.03 | 1 | ||
2019-02-27 | 2018-12-31 | 2.55 | 1.48 | -1.07 | 41 | ||
2018-10-31 | 2018-09-30 | 3.25 | 2.42 | -0.83 | 25 | ||
2018-08-01 | 2018-06-30 | 3.17 | 3.98 | 0.81 | 25 | ||
2018-05-02 | 2018-03-31 | 3.52 | 5.57 | 2.05 | 58 | ||
2018-02-21 | 2017-12-31 | 3.89 | 3.89 | 0.0 | 0 | ||
2017-10-25 | 2017-09-30 | 3.87 | 6.27 | 2.4 | 62 | ||
2017-07-27 | 2017-06-30 | 3.61 | 4.4 | 0.79 | 21 | ||
2017-04-26 | 2017-03-31 | 3.31 | 3.89 | 0.58 | 17 | ||
2017-02-22 | 2016-12-31 | 3.61 | 2.49 | -1.12 | 31 | ||
2016-10-27 | 2016-09-30 | 3.34 | 3.5 | 0.16 | 4 | ||
2016-07-28 | 2016-06-30 | 3.22 | 4.39 | 1.17 | 36 | ||
2016-04-28 | 2016-03-31 | 3.21 | 4.84 | 1.63 | 50 | ||
2016-02-25 | 2015-12-31 | 2.55 | 2.1 | -0.45 | 17 | ||
2015-10-27 | 2015-09-30 | 2.54 | 4.91 | 2.37 | 93 | ||
2015-07-28 | 2015-06-30 | 2.31 | 1.91 | -0.4 | 17 | ||
2015-04-28 | 2015-03-31 | 2.14 | -0.36 | -2.5 | 116 | ||
2015-02-24 | 2014-12-31 | 2.03 | 2.37 | 0.34 | 16 | ||
2014-10-28 | 2014-09-30 | 1.97 | -0.53 | -2.5 | 126 | ||
2014-07-29 | 2014-06-30 | 1.75 | 2.1 | 0.35 | 20 | ||
2014-04-29 | 2014-03-31 | 1.65 | 2.43 | 0.78 | 47 | ||
2014-02-25 | 2013-12-31 | 1.51 | -0.6 | -2.11 | 139 | ||
2013-10-29 | 2013-09-30 | 1.59 | 1.17 | -0.42 | 26 | ||
2013-07-25 | 2013-06-30 | 1.47 | 1.52 | 0.05 | 3 | ||
2013-04-25 | 2013-03-31 | 1.47 | 1.19 | -0.28 | 19 | ||
2013-02-26 | 2012-12-31 | 1.25 | 1.6 | 0.35 | 28 | ||
2012-11-01 | 2012-09-30 | 1.26 | 1.04 | -0.22 | 17 | ||
2012-07-26 | 2012-06-30 | 1.12 | 1.34 | 0.22 | 19 | ||
2012-04-26 | 2012-03-31 | 0.93 | 1.29 | 0.36 | 38 | ||
2012-02-14 | 2011-12-31 | 0.87 | 0.77 | -0.1 | 11 | ||
2011-10-27 | 2011-09-30 | 0.73 | 1.32 | 0.59 | 80 | ||
2011-07-28 | 2011-06-30 | 0.53 | 1.18 | 0.65 | 122 | ||
2011-04-28 | 2011-03-31 | 0.64 | 0.26 | -0.38 | 59 | ||
2011-02-15 | 2010-12-31 | 0.62 | 0.15 | -0.47 | 75 | ||
2010-10-28 | 2010-09-30 | 0.54 | 0.66 | 0.12 | 22 | ||
2010-07-28 | 2010-06-30 | 0.45 | 0.62 | 0.17 | 37 | ||
2010-04-29 | 2010-03-31 | 0.29 | 0.32 | 0.03 | 10 | ||
2010-02-16 | 2009-12-31 | 0.28 | -0.06 | -0.34 | 121 | ||
2009-10-29 | 2009-09-30 | 0.3 | 0.21 | -0.09 | 30 | ||
2009-07-31 | 2009-06-30 | 0.27 | -0.04 | -0.31 | 114 | ||
2009-05-01 | 2009-03-31 | 0.31 | 0.25 | -0.06 | 19 | ||
2009-02-17 | 2008-12-31 | 0.26 | -1.71 | -1.97 | 757 | ||
2008-10-30 | 2008-09-30 | 0.29 | 0.25 | -0.04 | 13 | ||
2008-07-31 | 2008-06-30 | 0.29 | 0.3 | 0.01 | 3 | ||
2008-05-01 | 2008-03-31 | 0.27 | 0.24 | -0.03 | 11 | ||
2008-02-19 | 2007-12-31 | 0.22 | 0.04 | -0.18 | 81 | ||
2007-11-01 | 2007-09-30 | 0.17 | 0.33 | 0.16 | 94 | ||
2007-07-31 | 2007-06-30 | 0.18 | 0.13 | -0.05 | 27 | ||
2007-05-01 | 2007-03-31 | 0.3 | 0.22 | -0.08 | 26 | ||
2007-02-20 | 2006-12-31 | 0.35 | 0.38 | 0.03 | 8 | ||
2006-10-31 | 2006-09-30 | 0.26 | 0.37 | 0.11 | 42 | ||
2006-08-01 | 2006-06-30 | 0.2 | 0.34 | 0.14 | 70 | ||
2006-05-02 | 2006-03-31 | 0.24 | 0.2 | -0.04 | 16 | ||
2006-02-21 | 2005-12-31 | 0.33 | 0.57 | 0.24 | 72 | ||
2005-10-31 | 2005-09-30 | 0.24 | 0.31 | 0.07 | 29 | ||
2005-08-02 | 2005-06-30 | 0.16 | 0.25 | 0.09 | 56 | ||
2005-05-03 | 2005-03-31 | 0.14 | 0.16 | 0.02 | 14 | ||
2005-02-22 | 2004-12-31 | 0.1 | 0.14 | 0.04 | 40 | ||
2004-11-03 | 2004-09-30 | 0.08 | 0.14 | 0.06 | 75 | ||
2004-05-06 | 2004-03-31 | -0.01 | -0.04 | -0.03 | 300 | ||
2004-02-24 | 2003-12-31 | -0.04 | -0.07 | -0.03 | 75 | ||
2003-11-06 | 2003-09-30 | -0.04 | -0.03 | 0.01 | 25 | ||
2003-08-05 | 2003-06-30 | -0.05 | -0.05 | 0.0 | 0 | ||
2003-05-06 | 2003-03-31 | -0.09 | -0.07 | 0.02 | 22 | ||
2003-02-25 | 2002-12-31 | -0.08 | -0.06 | 0.02 | 25 | ||
2002-11-08 | 2002-09-30 | -0.16 | -0.14 | 0.02 | 12 | ||
2001-08-10 | 2001-06-30 | -0.24 | -0.26 | -0.02 | 8 | ||
2001-05-09 | 2001-03-31 | -0.23 | -0.23 | 0.0 | 0 | ||
2001-03-21 | 2000-12-31 | -0.25 | -0.29 | -0.04 | 16 | ||
2000-11-02 | 2000-09-30 | -0.27 | -0.17 | 0.1 | 37 | ||
2000-08-09 | 2000-06-30 | -0.24 | -0.24 | 0.0 | 0 | ||
2000-05-09 | 2000-03-31 | -0.23 | -0.22 | 0.01 | 4 | ||
2000-03-02 | 1999-12-31 | -0.28 | -0.28 | 0.0 | 0 | ||
1999-11-08 | 1999-09-30 | -0.26 | -0.2 | 0.06 | 23 |
United Therapeutics Corporate Management
| Holly Hobson | Associate Resources | Profile | |
| JD MBA | Chairman Founder | Profile | |
| Gil Golden | Senior Officer | Profile | |
| Dewey CFA | Head Relations | Profile | |
| Kevin Gray | Senior Logistics | Profile |
Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.